Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Investigator-Blinded, Active-Controlled Study of Efficacy and Safety of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

NCT06466785 is registered in ClinicalTrials.gov with Genexine, Inc. as lead sponsor.

NCT NCT06466785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06466785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Investigator-Blinded, Active-Controlled Study of Efficacy and Safety of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
Lead sponsor
Genexine, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
January 25, 2024
Completion date
March 31, 2028
Enrollment
429 (estimated)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

anemia of chronic kidney disease